Summary
LIBRA PHARMA is a financial institution; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €1.2m and a net result of €137,007. Equity is growing by about 12% per year across the filed financial years. Its solvency ranks better than 35% of 6,680 sector peers (NACE 64, financial year 2025). The company has been active since 2011 and the Belgian Official Gazette contains no insolvency or warning signals.
Articles of association
What the company does
- DurationHow long the company exists; usually unlimited, so until it is dissolved.
- Unlimited
- Name clauseThe name the company operates under according to its articles.
- Libra Pharma
- Registered office clauseThe region of the registered office; it decides among other things the language of official documents.
- “Vlaamse Gewest” (deed in Dutch)
Who represents it, and how
- Board ruleHow the board is made up, meets and takes decisions.
- “Elke bestuurder bevoegd alle handelingen te verrichten nodig of dienstig tot verwezenlijking voorwerp,tenzij waarvoor volgens wet algemene…” (deed in Dutch)
Capital, shares and profit
- Transfer restrictionWhether shareholders may sell their shares freely or need approval first.
- “Inzake overdracht van aandelen gelden de in de statuten opgelegde regelingen” (deed in Dutch)
Meetings and financial year
- Annual meetingWhen the shareholders meet each year, among other things to approve the annual accounts.
- “De vennootschap wordt, binnen hun bevoegdheidssfeer, tevens rechtsgeldig vertegenwoordigd door de personen belast met het dagelijks bestuur…” (deed in Dutch)
Oversight and winding up
- Liquidation ruleHow assets are shared after dissolution: creditors first, then shareholders.
- “Ontbinding, algemene vergadering bepaalt wijze overeenkomstig wettelijke bepalingen” (deed in Dutch)